Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies

被引:19
|
作者
Liu, Yuan [1 ]
Liao, Xining [2 ]
Shi, Guixiu [1 ]
机构
[1] Xiamen Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, Xiamen, Peoples R China
[2] Xiamen Univ, Med Coll, Xiamen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2019年 / 10卷
关键词
spondyloarthritis; autoantibodies; diagnosis; anti-CD74; autoantibody; Chinese patients; ANKYLOSING-SPONDYLITIS; BETA-2; MICROGLOBULIN; INVARIANT CHAIN; RADIOGRAPHIC PROGRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; ANTI-MCV; SERUM; SCLEROSTIN; BIOMARKERS;
D O I
10.3389/fimmu.2019.00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Spondyloarthritis (SpA) is an inflammatory rheumatic disease with diverse clinical presentation. The diagnosis of SpA remains a big challenge in daily clinical practice because of the limitation in specific biomarkers of SpA, more biomarkers are still needed for SpA diagnosis and disease activity monitoring. In the past, SpA was considered predominantly as auto-inflammatory disease vs. autoimmune disease. However, in recent years several researches demonstrated a broad autoantibody response in SpA patients. Study also indicated that mice lack of ZAP70 in T cell develop SpA featured inflammation. These studies indicated the autoimmune features of SpA and gave rise to the potential use of autoantibody in SpA management. In this article, we reviewed recent reports of autoantibodies associated with SpA patients, revealing the autoimmune features of SpA, suggesting the hypothesis that SpA was also an autoimmune disease, studies about the autoimmune features might provide more insights in the pathogenesis of SpA. In addition, as there are two opposite conclusions in the role of anti-CD74 autoantibody in the diagnosis of SpA, we also gave our own data on the diagnostic value of anti-CD74 in Chinese SpA patients. Though our data indicated that anti-CD74 might not be a good biomarker for SpA diagnosis in Asian people, CD74 was still a good molecule target in the research of SpA pathogenesis.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] INTERSPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS
    Riechers, E.
    Baerlecken, N. T.
    Baraliakos, X.
    Bakhsh, Achilles-Mehr K.
    Aries, P. M.
    Bannert, B.
    Becker, K.
    Brandt-Juergens, J. F.
    Braun, J.
    Ehrenstein, B.
    Euler, H.
    Fleck, M.
    Hein, R.
    Karberg, K.
    Koehler, L.
    Matthias, T.
    Max, R.
    Melzer, A.
    Meyer-Olson, D.
    Rech, J.
    Rockwitz, K.
    Rudwaleit, M.
    Schweikhard, E.
    Sieper, J.
    Stille, C.
    von Hinueber, U.
    Wagener, P.
    Weidemann, H.
    Zinke, S.
    Witte, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 739 - 739
  • [32] Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells
    Brandish, Philip E.
    Palmieri, Anthony
    Antonenko, Svetlana
    Beaumont, Maribel
    Benso, Lia
    Cancilla, Mark
    Cheng, Mangeng
    Fayadat-Dilman, Laurence
    Feng, Guo
    Figueroa, Isabel
    Firdos, Juhi
    Garbaccio, Robert
    Garvin-Queen, Laura
    Gately, Dennis
    Geda, Prasanthi
    Haines, Christopher
    Hseih, SuChun
    Hodges, Douglas
    Kern, Jeffrey
    Knudsen, Nickolas
    Kwasnjuk, Kristen
    Liang, Linda
    Ma, Huiping
    Manibusan, Anthony
    Miller, Paul L.
    Moy, Lily Y.
    Qu, Yujie
    Shah, Sanjiv
    Shin, John S.
    Stivers, Peter
    Sun, Ying
    Tomazela, Daniela
    Woo, Hyun Chong
    Zaller, Dennis
    Zhang, Shuli
    Zhang, Yiwei
    Zielstorff, Mark
    BIOCONJUGATE CHEMISTRY, 2018, 29 (07) : 2357 - 2369
  • [33] INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS
    Riechers, E.
    Baerlecken, N. T.
    Baraliakos, X.
    Bakhsh, K. Achilles-Mehr
    Aries, P. M.
    Bannert, B.
    Becker, K.
    Brandt-Jurgens, F.
    Braun, J.
    Ehrenstein, B.
    Euler, H.
    Fleck, M.
    Hein, R.
    Karberg, K.
    Kohler, L.
    Matthias, T.
    Max, R.
    Melzer, A.
    Meyer-Olson, D.
    Rech, J.
    Rockwitz, K.
    Rudwaleit, M.
    Schweikhard, E.
    Sieper, J.
    Stille, C.
    von Hinueber, U.
    Wagener, P.
    Weidemann, H.
    Zinke, S.
    Witte, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 338 - 339
  • [34] Sensitivity of NHL to killing by anti-HLA-DR and anti-CD74 mAbs is increased by interferon-gamma
    Stein, Rhona
    Modrak, David
    Chen, Susan
    Gold, David V.
    Goldenberg, David M.
    CANCER RESEARCH, 2010, 70
  • [35] Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma
    Kaufman, J. L.
    Niesvizky, R.
    Stadtmauer, E. A.
    Chanan-Khan, A.
    Siegel, D.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma.
    Kaufman, Jonathan
    Niesvizky, Ruben
    Stadtmauer, Edward A.
    Chanan-Khan, Asher
    Siegel, David
    Home, Heather
    Teoh, Nick
    Leoni, Matthew J.
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2008, 112 (11) : 1266 - 1267
  • [37] Milatuzumab (humanized anti-CD74 mAb) targets and kills B-cell malignancies, and blocks signal transduction through CD74
    Stein, Rhona
    Karacay, Habibe
    Sharkey, Robert
    Smith, Mitchell
    Goldenberg, David
    CANCER RESEARCH, 2009, 69
  • [38] CD74 AS AN AUTOANTIGEN IN SPONDYLOARTHRITIS
    Witte, T.
    Wintering, O.
    Kniesch, K.
    Klose, K.
    Baerlecken, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 814 - 814
  • [39] CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, STRO-001
    Embry, Millicent
    Li, Xiaofan
    Yu, Abigail
    Abrahams, Cristina
    Greenland, Nancy Y.
    Wen, Kwun Wah
    Jones, Chris
    DeAlmeida, Venita
    Krimm, Stellanie
    Krueger, Sarah
    Matheny, Shannon
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Wiita, Arun P.
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    BLOOD, 2017, 130
  • [40] Anti-CD74 antibody therapy with hLL1 (milatuzumab) for treatment of B-cell malignancies
    Martin, P.
    Furman, R.
    Elstrom, R.
    Ruan, J.
    Shore, T.
    Ely, S.
    Glynn, P.
    Niesvizky, R.
    Coleman, M.
    Sharkey, R.
    Vallabhajosula, S.
    Goldsmith, S.
    Goldenberg, D. M.
    Leonard, J. P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 525 - 525